Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation

Table 2 Clinical characteristics of the patient groups, n (%)

Variable	Age group (yr)		Total
	< 75	≥ 75
Primary cause of ESRD
Diabetic nephropathy	6 (19.4)	1 (9.1)	7 (16.7)
Hypertension	6 (19.4)	2 (18.2)	8 (19.0)
Glomerulonephritis	4 (12.9)	3 (27.3)	7 (16.7)
Polycystic kidney disease	6 (19.4)	2 (18.2)	8 (19.0)
Chronic Interstitial nephritis	3 (9.7)	1 (9.1)	4 (9.5)
Reflux/Congenital	3 (9.7)	2 (18.2)	3 (7.1)
Other	3 (9.7)	2 (18.2)	5 (11.9)
NOACs
Dabigatran 150 mg bid	1 (3.2)	1 (3.2)	2 (4.8)
Dabigatran-Low Dose	1 (3.2)	0 (0.0)	1 (2.4)
Apixaban 5 mg bid	11 (35.5)	1 (9.1)	12 (28.6)
Apixaban-Low Dose	10 (32.3)	7 (63.6)	17 (40.5)
Rivaroxaban 20 mg/d	5 (16.1)	0 (0.0)	5 (11.9)
Rivaroxaban Low Dose	3 (9.7)	2 (18.2)	5 (11.9)
Cause of NOAC initiation
VTE	8 (25.8)	2 (18.2)	10 (23.8)
AF	17 (54.8)	8 (72.7)	25 (59.5)
Other	2 (6.5)	0 (0)	2 (4.8)
VTE and AF	4 (12.9)	1 (9.1)	5 (11.9)
Calcineurin inhibitors
Advagraf	22 (71.0)	5 (45.5)	27 (64.3)
Prograf	3 (9.7)	1 (9.1)	4 (9.5)
Cyclosporin	1 (3.2)	4 (36.4)	5 (11.9)
Sirolimus	3 (9.7)	1 (9.1)	4 (9.5)
None	2 (4.8)	0 (0)	2 (4.8)
Clopidogrel
Yes	4 (12.9)	1 (9.1)	5 (11.9)
No	27 (87.1)	10 (90.9)	37 (88.1)

NOACs: Novel oral anticoagulants; VTE: Venous thromboembolism; AF: Atrial fibrillation; ESRD: End stage renal disease.